Here's Why Shares in Recursion Pharmaceuticals Surged Today
2025-07-08 13:28:49 ET
Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.
The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB) . REV102 is being developed to treat hypophosphatasia (HPP) -- a rare and debilitating genetic disorder that affects bone development.
According to Recursion, "HPP is a devastating genetic disorder affecting over 7,800 diagnosed patients across the U.S. and major European countries." It targets an enzyme, ENPP1, whose inhibition is believed to help treat HPP.
NASDAQ: RLYB
RLYB Trading
-1.19% G/L:
$9.97 Last:
35,238 Volume:
$9.79 Open:
